SMALL CAP MOVERS: Synairgen tanks; Eve Sleep soars
Synairgen tanked 83 per cent to 29.24p after it said its treatment for Covid failed to meet both its primary and secondary goals in a phase III clinical trial.
Source: dailymail.co.uk
Stay updated with breaking news from Invinity Vanadium Flow Battery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Synairgen tanked 83 per cent to 29.24p after it said its treatment for Covid failed to meet both its primary and secondary goals in a phase III clinical trial.
Synairgen tanked 83 per cent to 29.24p after it said its treatment for Covid failed to meet both its primary and secondary goals in a phase III clinical trial.